Literature DB >> 3141348

In-vitro antimicrobial activity of 7432-S (SCH39720) against commonly isolated respiratory tract pathogens.

R N Jones, A L Barry.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3141348     DOI: 10.1093/jac/22.3.387-a

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  5 in total

1.  Interpretive criteria and quality control limits for ceftibuten disk susceptibility tests. Collaborative Antimicrobial Susceptibility Testing Group.

Authors:  A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

Review 2.  Ceftibuten pharmacokinetics and pharmacodynamics. Focus on paediatric use.

Authors:  G L Kearns; R A Young
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

3.  Pharmacokinetics of ceftibuten-cis and its trans metabolite in healthy volunteers and in patients with chronic renal insufficiency.

Authors:  J S Kelloway; W M Awni; C C Lin; J Lim; M B Affrime; W F Keane; G R Matzke; C E Halstenson
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

4.  MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin.

Authors:  M J Bale; R N Jones; M E Erwin; F P Koontz; E H Gerlach; P R Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

5.  Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infections.

Authors:  C O Onyeji; D P Nicolau; C H Nightingale; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.